1. Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment
- Author
-
Julius July, Diana Patricia, Pricilla Yani Gunawan, Handrianto Setiajay, Teridah Ernala Ginting, Teguh Pribadi Putra, Zerlina Wuisan, Dini Budhiarko, Najmiatul Masykura, Gintang Prayogi, Ahmad Rusdan Utomo, Steven Tandean, and Michael Lumintang Loe
- Subjects
idh1 mutation ,mgmt methylation ,pd-l1 ,anaplastic astrocytoma ,glioblastoma multiforme ,Medicine - Abstract
INTRODUCTION: The objective was to evaluate the impact of IDH1 R132H mutation, MGMT methylation and PD-L1 expression in high grade glioma that received standard therapy (surgery, radiation and chemotherapy) to overall survival (OS). METHODS: this is a retrospective study of 35 high grade glioma cases. Genotyping of IDH1 gene alteration on the mutation hotspot R132 (Sanger sequencing method with Applied Biosystems 3500 Genetic Analyzer), EZ DNA Methylation-Gold kit (Zymo Research) is used to study the methylation, Cell line BT549 (ATCC HTB-122) and HCT-116 (ATCC CCL-247) were used as unmethylated control and partially methylated control respectively. Anti-human PD-L1 antibody clone E1L3N® from Cell Signalling Technology (USA) and Rabbit XP® were used to see PDL-1 expression. RESULTS: anaplastic astrocytoma cases had more MGMT promoter methylation (50%) than glioblastoma multiforme (GBM) (20%), more IDH1 R132H mutation (42%) than GBM (4.3%). Immunohistochemistry tumor proportion score method (TPS) identified 17% and 8.7% were PD-L1 positive in AA and GBM groups, respectively. Cases with IDH1 R132H mutation and MGMT methylation still showed better OS although with high PD-L1 expression.
- Published
- 2020
- Full Text
- View/download PDF